Related Experiment Videos
Targeting pediatric malignancies for T cell-mediated immune responses
1Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA. cm35c@nih.gov
Current Oncology Reports
|December 21, 2000
Summary
This study explores three immunotherapy strategies for targeting tumors by activating T-cells. These methods aim to attack cancer while sparing healthy tissues, with a focus on pediatric oncology applications.
Area of Science:
- Tumor Immunology
- Cancer Immunotherapy
- Pediatric Oncology
Background:
- Successful cancer immunotherapy requires T-cell activation against tumors while sparing healthy tissues.
- Current research focuses on three distinct strategies to achieve tumor-specific immune responses.
Purpose of the Study:
- To review and discuss three main approaches for developing T-cell-based cancer immunotherapies.
- To evaluate the benefits and limitations of each approach, particularly for pediatric tumors.
Main Methods:
- Approach 1: Utilizing identified tumor antigens recognized by T-cells from cancer patients as immunogens.
- Approach 2: Employing tumor-specific molecules (e.g., mutant p53, chromosomal translocations) as immunogens.
- Approach 3: Administering whole tumor cell components to elicit an immune response.
Main Results:
- Approach 1 identified diverse tumor antigens, applicable beyond initial targets like melanoma and renal cell carcinoma.
- Approach 2 highlights tumor-specific molecules, with chromosomal translocations being particularly relevant for pediatric cancers.
- Approach 3 assumes dominant immunogenic molecules within whole tumor cells will drive the immune response.
Conclusions:
- Each immunotherapy approach presents unique benefits and challenges for clinical application.
- The identified strategies offer potential for advancing T-cell-mediated cancer immunotherapy, especially in pediatric oncology.